Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Drug resistance in pancreatic cancer: Impact of altered energy metabolism
Cristoforo Grasso, Gerrit Jansen, Elisa Giovannetti
Critical Reviews in Oncology/Hematology (2017) Vol. 114, pp. 139-152
Open Access | Times Cited: 222

Showing 1-25 of 222 citing articles:

Modulating ROS to overcome multidrug resistance in cancer
Qingbin Cui, Jing‐Quan Wang, Yehuda G. Assaraf, et al.
Drug Resistance Updates (2018) Vol. 41, pp. 1-25
Closed Access | Times Cited: 560
Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches
Michael Orth, Philipp Metzger, S. Gerum, et al.
Radiation Oncology (2019) Vol. 14, Iss. 1
Open Access | Times Cited: 399
Tumor-stromal crosstalk in pancreatic cancer and tissue fibrosis
Divya Thomas, Prakash Radhakrishnan
Molecular Cancer (2019) Vol. 18, Iss. 1
Open Access | Times Cited: 340
Metabolism of pancreatic cancer: paving the way to better anticancer strategies
Qin Cheng, Gang Yang, Jinshou Yang, et al.
Molecular Cancer (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 294
Impact of gastrointestinal physiology on drug absorption in special populations––An UNGAP review
Cordula Stillhart, Katarina Vučićević, Patrick Augustijns, et al.
European Journal of Pharmaceutical Sciences (2020) Vol. 147, pp. 105280-105280
Open Access | Times Cited: 219
Undermining Glutaminolysis Bolsters Chemotherapy While NRF2 Promotes Chemoresistance in KRAS-Driven Pancreatic Cancers
Suman Mukhopadhyay, Debanjan Goswami, Pavan P. Adiseshaiah, et al.
Cancer Research (2020) Vol. 80, Iss. 8, pp. 1630-1643
Open Access | Times Cited: 208
PDK4 dictates metabolic resistance to ferroptosis by suppressing pyruvate oxidation and fatty acid synthesis
Xinxin Song, Jiao Liu, Feimei Kuang, et al.
Cell Reports (2021) Vol. 34, Iss. 8, pp. 108767-108767
Open Access | Times Cited: 171
Post‐translational modifications of histones: Mechanisms, biological functions, and therapeutic targets
Ruiqi Liu, Jiajun Wu, H. Henry Guo, et al.
MedComm (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 104
The role of lncRNA-mediated ceRNA regulatory networks in pancreatic cancer
Jichuan Xu, Jian Xu, Xinyuan Liu, et al.
Cell Death Discovery (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 88
Cancer-Associated Fibroblasts: Mechanisms of Tumor Progression and Novel Therapeutic Targets
Ralf‐Peter Czekay, Dong‐Joo Cheon, Rohan Samarakoon, et al.
Cancers (2022) Vol. 14, Iss. 5, pp. 1231-1231
Open Access | Times Cited: 79
NUSAP1-LDHA-Glycolysis-Lactate feedforward loop promotes Warburg effect and metastasis in pancreatic ductal adenocarcinoma
Ming Chen, Kaili Cen, Yinjing Song, et al.
Cancer Letters (2023) Vol. 567, pp. 216285-216285
Closed Access | Times Cited: 62
ABCB1 overexpression through locus amplification represents an actionable target to combat paclitaxel resistance in pancreatic cancer cells
Cecilia Bergonzini, Alessandro Gregori, Tessa M. S. Hagens, et al.
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 16
Redox-Mediated Mechanism of Chemoresistance in Cancer Cells
Eun-Kyung Kim, Mingyeong Jang, Min-Jeong Song, et al.
Antioxidants (2019) Vol. 8, Iss. 10, pp. 471-471
Open Access | Times Cited: 131
Metabolic Reprogramming of Cancer Associated Fibroblasts: The Slavery of Stromal Fibroblasts
Angelica Avagliano, Giuseppina Granato, Maria Rosaria Ruocco, et al.
BioMed Research International (2018) Vol. 2018, pp. 1-12
Open Access | Times Cited: 121
LAT2 regulates glutamine-dependent mTOR activation to promote glycolysis and chemoresistance in pancreatic cancer
Mengyu Feng, Guangbing Xiong, Zhe Cao, et al.
Journal of Experimental & Clinical Cancer Research (2018) Vol. 37, Iss. 1
Open Access | Times Cited: 110
Pancreatic cancer in 2021: What you need to know to win
Valeria Tonini, Manuel Zanni
World Journal of Gastroenterology (2021) Vol. 27, Iss. 35, pp. 5851-5889
Open Access | Times Cited: 102
Therapeutic resistance of pancreatic cancer: Roadmap to its reversal
Sen Yu, Chunyu Zhang, Keping Xie
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2020) Vol. 1875, Iss. 1, pp. 188461-188461
Closed Access | Times Cited: 97
The role of metabolism and tunneling nanotube-mediated intercellular mitochondria exchange in cancer drug resistance
Yalda Hekmatshoar, Jean Nakhle, Mireille Galloni, et al.
Biochemical Journal (2018) Vol. 475, Iss. 14, pp. 2305-2328
Closed Access | Times Cited: 93
The dichotomous role of the glycolytic metabolism pathway in cancer metastasis: Interplay with the complex tumor microenvironment and novel therapeutic strategies
Btissame El Hassouni, Carlotta Granchi, Andrea Vallés‐Martí, et al.
Seminars in Cancer Biology (2019) Vol. 60, pp. 238-248
Closed Access | Times Cited: 92
Multiplex Stimulated Raman Scattering Imaging Cytometry Reveals Lipid-Rich Protrusions in Cancer Cells under Stress Condition
Kai‐Chih Huang, Junjie Li, Chi Zhang, et al.
iScience (2020) Vol. 23, Iss. 3, pp. 100953-100953
Open Access | Times Cited: 91
Copper oxide nanoparticles inhibit pancreatic tumor growth primarily by targeting tumor initiating cells
Madeleine Benguigui, Iris S. Weitz, Michael Timaner, et al.
Scientific Reports (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 86
‘Reverse Warburg effect’ of cancer‑associated fibroblasts (Review)
Lin Liang, Wentao Li, Xin Li, et al.
International Journal of Oncology (2022) Vol. 60, Iss. 6
Open Access | Times Cited: 68
Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment
Mubin Tarannum, Juan L. Vivero‐Escoto
Advanced Drug Delivery Reviews (2022) Vol. 187, pp. 114357-114357
Open Access | Times Cited: 40
Discovery of the 3-Amino-1,2,4-triazine-Based Library as Selective PDK1 Inhibitors with Therapeutic Potential in Highly Aggressive Pancreatic Ductal Adenocarcinoma
Daniela Carbone, Michele De Franco, Camilla Pecoraro, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 4, pp. 3679-3679
Open Access | Times Cited: 30
Advantages of Nanomedicine in Cancer Therapy: A Review
Chao Wang, Shan Zhang
ACS Applied Nano Materials (2023) Vol. 6, Iss. 24, pp. 22594-22610
Closed Access | Times Cited: 30
Page 1 - Next Page

Scroll to top